Therefore, it can be concluded that lipoic acid has potential as an adjunct therapy for MS, as it reduces MMP-9 and ICAM-1 activity, thus mitigating T cell entry into the CNS. The gene discussed is ICAM1; the disease is myeloid sarcoma.